<DOC>
	<DOCNO>NCT01074697</DOCNO>
	<brief_summary>GAND-emesis multinational , randomize , double-blind , placebo-controlled , parallel-group study investigate efficacy tolerability neurokinin1 receptor antagonist ( fosaprepitant dimeglumine ) combination antiemetic ( anti-nausea-and-vomiting ) control regimen ( palonosetron dexamethasone ) patient gynaecological cancer diagnosis , schedule receive radiotherapy weekly chemotherapy . The study aim investigate three-drug antiemetic regimen superior two-drug regimen ( standard treatment ) prevent nausea vomit patient receive radiotherapy weekly chemotherapy . A pilot study demonstrate approximately 50 % patient experience nausea vomit offer two-drug antiemetic regimen , expect addition third drug ( neurokinin1 receptor antagonist ) increase proportion patient vomit course combine chemo-radiotherapy .</brief_summary>
	<brief_title>Efficacy Two Antiemetic Regimens Patients Receiving Radiotherapy Concomitant Weekly Cisplatin</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>( abbreviate ) 1 . The patient diagnosis cervical cancer . 2 . The patient understands nature purpose study study procedure sign informed consent . 3 . The patient age &gt; 18 year . 4 . The patient must chemo radiotherapy ( RT ) naïve . NB : previously low voltage RT electron RT nonmelanoma skin cancer allow . 5 . The patient schedule receive fractionate radiotherapy concomitant weekly cisplatin dose ≥ 40 mg/m2 least five week . 6 . Brachy therapy schedule initiated third cycle weekly cisplatin , preferentially fifth week treatment . 7 . Chemotherapy emetic risk potential minimal mild ( 30 % ) allow day 14 ( see ref . 14 ) . 8 . The patient WHO Performance Status ≤ 2 . ( abbreviate ) 1 . The patient current malignant diagnosis cervical cancer , exception nonmelanoma skin cancer . 2 . The patient age &lt; 18 year . 3 . The patient schedule receive less five week fractionate radiotherapy concomitant weekly cisplatin . 4 . Brachy therapy plan initiated third cycle weekly cisplatin . 5 . The patient previously treat radiotherapy , and/or chemotherapy , exception treatment low voltage RT electron RT nonmelanoma skin cancer . 6 . The patient WHO Performance Status &gt; 2 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Serotonin Agonists</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Receptors , Neurokinin-1</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Prevention &amp; control</keyword>
</DOC>